Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MED Stock Forecast 2026-2027
$12.59
Current Price
$139.99M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MED Price Targets
-4.7%
To High Target of $12.00
-4.7%
To Median Target of $12.00
-4.7%
To Low Target of $12.00
MED Price Momentum
+18.4%
1 Week Change
+25.1%
1 Month Change
-1.3%
1 Year Change
+17.9%
Year-to-Date Change
-18.6%
From 52W High of $15.46
+36.6%
From 52W Low of $9.22
📊 TOP ANALYST CALLS
Did MED Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Medifast is one of their latest high-conviction picks.
Latest MED Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, MED has a neutral consensus with a median price target of $12.00 (ranging from $12.00 to $12.00). The overall analyst rating is Buy (6.0/10). Currently trading at $12.59, the median forecast implies a -4.7% downside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jim Salera at Stephens & Co., projecting a 4.7% downside. Conversely, the most conservative target is provided by Jim Salera at Stephens & Co., suggesting a 4.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MED Analyst Ratings
0
Buy
1
Hold
0
Sell
MED Price Target Range
Low
$12.00
Average
$12.00
High
$12.00
Current: $12.59
Latest MED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | Jim Salera | Equal-Weight | Maintains | $12.00 |
| Feb 19, 2025 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $16.50 |
| Nov 5, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Upgrade | $17.00 |
| Jul 22, 2024 | DA Davidson | Linda Bolton Weiser | Underperform | Maintains | $17.50 |
| Jun 5, 2024 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $17.50 |
| Apr 30, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $25.00 |
| Feb 21, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $40.00 |
| Oct 13, 2023 | Stephens & Co. | Jim Salera | Equal-Weight | Initiates | $82.00 |
| Aug 8, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $80.00 |
| Jul 31, 2023 | DA Davidson | Neutral | Maintains | $N/A | |
| May 2, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $71.00 |
| Feb 22, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $94.00 |
| Nov 4, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Downgrade | $106.00 |
| Aug 4, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $278.00 |
| Aug 4, 2022 | Jefferies | Stephanie Wissink | Hold | Downgrade | $150.00 |
| Jun 2, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $352.00 |
| Feb 24, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $341.00 |
| Nov 8, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $349.00 |
| May 5, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $395.00 |
| Feb 26, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $302.00 |
Medifast Inc. (MED) Competitors
The following stocks are similar to Medifast based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medifast Inc. (MED) Financial Data
Medifast Inc. has a market capitalization of $139.99M with a P/E ratio of 531.5x. The company generates $346.10M in trailing twelve-month revenue with a -5.8% profit margin.
Revenue growth is -34.3% quarter-over-quarter, while maintaining an operating margin of -7.2% and return on equity of -9.8%.
Valuation Metrics
Market Cap
$139.99M
Enterprise Value
$-23,758,282
P/E Ratio
531.5x
PEG Ratio
3.1x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-34.3%
Gross Margin
+68.1%
Operating Margin
-7.2%
Net Margin
-5.8%
EPS Growth
-34.3%
Financial Health
Cash/Price Ratio
+130.9%
Current Ratio
4.8x
Debt/Equity
8.1x
ROE
-9.8%
ROA
-4.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Medifast Inc. (MED) Business Model
About Medifast Inc.
What They Do
Provides weight management and healthy living products.
Business Model
Medifast operates primarily through a direct selling model using OPTAVIA Coaches who provide personalized support and guidance to customers. This approach allows the company to generate revenue from its range of meal replacement products, snacks, and hydration solutions, catering to individuals looking for sustainable lifestyle changes.
Additional Information
The company's focus on nutritional science and educational support distinguishes it in the competitive health sector. With an increasing consumer interest in health products, Medifast's adaptability and innovative strategies position it well for continued growth in the global health and wellness market.
Company Information
Sector
Consumer Cyclical
Industry
Personal Services
Employees
380
CEO
Mr. Daniel R. Chard
Country
United States
IPO Year
1993
Website
medifastinc.comMedifast Inc. (MED) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.
May 05, 2026
By Zacks Equity Research
Analyst Blog
Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates
Medifast (MED) delivered earnings and revenue surprises of +65.46% and +3.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
MED reports Q1 fiscal 2026 May 4; revenue seen down 36.3% and EPS at a 55-cent loss as coach base and demand stay pressured.
May 01, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
MED exceeded first-quarter estimates despite significant revenue declines. Improved coach productivity and a new product launch raise recovery expectations.
Why It Matters
MED's earnings beat expectations amid revenue drops, indicating resilience. Improved coach productivity and new products suggest potential for future growth, which can positively influence stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Medifast, Inc. (MED) held its Q1 2026 earnings call, detailing financial performance and strategic updates. Full details are available in the transcript.
Why It Matters
The earnings call provides insights into Medifast's financial performance, growth strategies, and market outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Medifast (NYSE: MED) reported Q1 2026 revenue of $76 million, with a net loss of $2.1 million ($0.19 EPS). The company has $168.9 million in cash and no debt.
Why It Matters
Medifast's Q1 2026 revenue decline and net loss indicate potential challenges in profitability. However, strong cash reserves and no debt suggest financial stability, impacting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Medifast (MED) reported a quarterly loss of $0.19 per share, exceeding the Zacks estimate of $0.55 loss, compared to a loss of $0.11 per share in the same quarter last year.
Why It Matters
Medifast's smaller-than-expected quarterly loss indicates potential operational improvements, which may boost investor confidence and affect stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MED's Q1 fiscal 2026 report on May 4 anticipates a 36.3% revenue decline and an EPS loss of 55 cents due to ongoing pressure on its coach base and demand.
Why It Matters
MED's projected revenue decline and EPS loss indicate weakening demand, potentially impacting stock performance and investor sentiment negatively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Medifast (NYSE: MED) will release Q1 2026 financial results on May 4, 2026, after market close, followed by a conference call featuring key executives.
Why It Matters
Medifast's upcoming financial results announcement could impact stock performance, offering insights into company health and growth prospects, influencing investor sentiment and decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MED Stock
What is Medifast Inc.'s (MED) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Medifast Inc. (MED) has a median price target of $12.00. The highest price target is $12.00 and the lowest is $12.00.
Is MED stock a good investment in 2026?
According to current analyst ratings, MED has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MED stock?
Wall Street analysts predict MED stock could reach $12.00 in the next 12 months. This represents a -4.7% decrease from the current price of $12.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medifast Inc.'s business model?
Medifast operates primarily through a direct selling model using OPTAVIA Coaches who provide personalized support and guidance to customers. This approach allows the company to generate revenue from its range of meal replacement products, snacks, and hydration solutions, catering to individuals looking for sustainable lifestyle changes.
What is the highest forecasted price for MED Medifast Inc.?
The highest price target for MED is $12.00 from Jim Salera at Stephens & Co., which represents a -4.7% decrease from the current price of $12.59.
What is the lowest forecasted price for MED Medifast Inc.?
The lowest price target for MED is $12.00 from Jim Salera at Stephens & Co., which represents a -4.7% decrease from the current price of $12.59.
What is the overall MED consensus from analysts for Medifast Inc.?
The overall analyst consensus for MED is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are MED stock price projections?
Stock price projections, including those for Medifast Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:16 AM UTC